<DOC>
	<DOCNO>NCT03061201</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability time-course profile FVIII activity level adaptive dos SB-525 .</brief_summary>
	<brief_title>Dose-Ranging Study Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 Subjects With Severe Hemophilia A</brief_title>
	<detailed_description>The objective study reduce eliminate need FVIII replacement therapy . The propose SB-525 clinical study use recombinant adeno-associated virus 2/6 ( AAV2/6 ) vector encode cDNA B-domain delete human F8 ( hF8 ) . The secreted FVIII amino acid sequence approve recombinant anti hemophilic factor ( Refacto® Xyntha® ) . The SB-525 vector encodes liver-specific promotor module AAV2/6 exhibit liver tropism , thus provide potential long-term hepatic production FVIII hemophilia A subject . The constant production FVIII single SB-525 administration may provide potential benefit durable protection bleed complication thereof without lifelong repetitive IV factor replacement administration .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male ≥18 year age Severe hemophilia A ( past evidence circulate FVIII activity &lt; 1 % normal ) Treated exposed FVIII concentrate cryoprecipitate least 150 exposure day ≥12 bleed episode receive ondemand therapy precede 12 month Agree use double barrier contraceptive least 3 consecutive semen sample negative AAV 2/6 SB525 infusion Presence neutralizing antibody Current inhibitor , history FVIII inhibitor ( except transient low titer inhibitor detect childhood ) History hypersensitivity response FVIII History Hepatitis B HIV1/2 infection History Hepatitis C , unless viral assay two sample , collect least 6 month apart , negative Evidence bleed disorder addition hemophilia A Markers hepatic inflammation overt occult cirrhosis History chronic renal disease creatinine ≥ 1.5 mg/dL Presence liver mass magnetic resonance imaging ( MRI ) , , positive alpha fetoprotein Presence &gt; grade 2 liver fibrosis elastography subject history treat Hepatitis C suspicion chronic liver disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>